Chris_Halkides
Penultimate Amazing
- Joined
- Dec 8, 2009
- Messages
- 12,615
At Inside Medicine Dr. Jeremy Faust wrote, "As an important MedPage Today story by Rachael Robertson reports, the agency has convened a handful of “expert panels” on high-profile topics as of late, including antidepressants in pregnancy. These panels function differently from advisory committees, groups whose activities are governed by official policies designed to ensure quality, transparency, and public participation. The problem is that, unlike advisory committees whose work must follow certain rules (such as providing adequate advance notice), these panels seem to be hastily thrown together PR events. That said, their influence on any genuine regulatory activity, if any, remains opaque."
At MedPageToday Rachel Robertson wrote, "There have been about four panels so far: one on selective serotonin reuptake inhibitorsopens in a new tab or window (SSRIs) and pregnancy; another on hormone therapyopens in a new tab or window for menopause; one on infant formulaopens in a new tab or window; and another on talcopens in a new tab or window in food, drugs, and cosmetics..."It felt like they only wanted invited guests there in the same way that the panel was all invited to have a particular point of view," [Diana] Zuckerman [PhD] said. "When you have a meeting where everybody's selected to have a consistent point of view with each other and presumably with the commissioner, and nobody from the public is allowed to say a word, and most people from the public aren't even allowed to be in the room, that's ... not the transparency that this FDA promised.""
At MedPageToday Rachel Robertson wrote, "There have been about four panels so far: one on selective serotonin reuptake inhibitorsopens in a new tab or window (SSRIs) and pregnancy; another on hormone therapyopens in a new tab or window for menopause; one on infant formulaopens in a new tab or window; and another on talcopens in a new tab or window in food, drugs, and cosmetics..."It felt like they only wanted invited guests there in the same way that the panel was all invited to have a particular point of view," [Diana] Zuckerman [PhD] said. "When you have a meeting where everybody's selected to have a consistent point of view with each other and presumably with the commissioner, and nobody from the public is allowed to say a word, and most people from the public aren't even allowed to be in the room, that's ... not the transparency that this FDA promised.""